Zetagen Therapeutics, discovered novel ZetaMet™ technology for the treatment of metastatic bone cancers. This technology is the first to suspend cancer inhibit pain, and regenerate bone.
ZetaMet™ technology was earlier known as ZetaFuse. It is a synthetic, small-molecule, inductive biologic technology introduced to target and resolve metastatic bone lesions which restricts the further growth of tumor growth and regenerating bone.
ZetaMet™ is a novel and patented molecular pathway. The small molecule dosage is delivered with a proprietary drug-eluting carrier to the affected area which stimulates cells for the healthy bone growth known as “osteoblasts” and the growth of cells with bone degradation called “osteoclasts”.
Bone metastases are often found among cancer patients and occur when cells from primary cancerous tumor relocate to the bone. During the process of relocation, it can cause bone damage known as osteolysis. Osteolysis causes small holes inside the bone thereby weakening it and increasing the risk of breakage. These holes are known as lytic lesions.
US Food and Drug Administration (FDA) has approved ZetaMet™ KYNMOBI™ for the treatment of metastatic bone cancers.